MRNA Sep 2024 110.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 09:39AM EDT. Market open.
| Previous close | 5.08 |
| Open | 5.30 |
| Bid | 4.40 |
| Ask | 4.65 |
| Strike | 110.00 |
| Expiry date | 2024-09-20 |
| Day's range | 5.30 - 5.30 |
| Contract range | N/A |
| Volume | |
| Open interest | 870 |
ZacksThe Zacks Analyst Blog Highlights Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers
Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers are included in this Analyst Blog.
ZacksBiotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY
Novavax, Inc (NVAX) and Fulcrum Therapeutics, Inc (FULC) are in the spotlight following license agreements with pharma giant Sanofi.
BenzingaPfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
On Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical companies who announced they will be investing a total of nearly $1 billion in their operations in France, just ahead of this year’s “Choose France” business summit. Together with the domestic Sanofi (NASDAQ: SNY), Pfizer, AstraZeneca will together invest €1.87 billion which is more than $2 billion to expand their operations in the country. AstraZeneca committed 365 million euros, which is about $394 mi
© 2024 Yahoo. All rights reserved.